．

Material Information - The Company Announces Filing of New Drug Submission of BESREMi (Ropeginterferon alfa-2b) for PV in Canada

Jul 18, 2025

20250718 本公司新藥BESREMi申請加拿大上市許可證，適應症為PV (EN).pdf

Download